Aim
To compare conventional measures with MRI and US in the assessment of treatment efficacy in JIA.
Methods
Patients with JIA and active wrist arthritis who started receiving a second line therapy (DMARDs or biological agent) at the study Unit between 2008 and 2010 were enrolled in the study. The clinically more affected wrist was studied with MRI (1.5 T), US and conventional radiography (CR), coupled with standard clinical assessment at the study enrollment and after 1 year. Patients were characterized according to the pACR response criteria, and to the current criteria for inactive disease.
Results
Thirty seven patients (median age 10.8 years, median disease duration 4.1 years) were enrolled. Thirteen patients out of 37 patients (35.1%) started DMARDs while 24/37 patients (64.8%) started biologic agents.
Patients who met the definition of improvement according to the pACR90 criteria (N=13) showed a significantly greater decrease in MRI synovitis score compared to patients who met the pACR 30, 50 and 70 criteria (N=14) (p<0.0023), and compared to the non-responders (N=10) (p<0.002), indicating the ability of MRI synovitis score to discriminate between different levels of responder categories. Excluding physician's global assessment of disease activity, MRI synovitis score was more responsive (SRM 1.61) than ACR core set measures and US synovitis score (SRM gray scale 0.87; SRM Doppler 0.71). After 1 year 11/37 patients met the critera for inactive disease. Of these, only 1 showed no synovitis according to MRI and 4 according to US. MRI and CR performed equally in detecting structural damage progression after 1 year.
Conclusions
The excellent responsiveness and discriminant ability of MRI synovitis score makes it promising as an outcome measure in clinical studies. Only the high degree responders showed a significant decrease in synovitis score. Clinical criteria are insensitive to detect low level of inflammation accurately, suggesting the potential role of imaging in the assessment of remission. 
